Joinn Laboratories (China) Co (SHSE:603127) 3-Year Revenue Growth Rate : 22.50% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co 3-Year Revenue Growth Rate?

Joinn Laboratories (China) Co's Revenue per Share for the three months ended in Mar. 2024 was ¥0.43.

During the past 12 months, Joinn Laboratories (China) Co's average Revenue per Share Growth Rate was 10.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 22.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 38.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 28.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Joinn Laboratories (China) Co was 46.70% per year. The lowest was 13.50% per year. And the median was 25.60% per year.

Competitive Comparison of Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate falls into.

Joinn Laboratories (China) Co 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Joinn Laboratories (China) Co (SHSE:603127) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Joinn Laboratories (China) Co 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co (SHSE:603127) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

06127:Hong Kong

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines